These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16091254)

  • 1. Immune-based therapies: an adjunct to antiretroviral treatment.
    Jacobson JM
    Curr HIV/AIDS Rep; 2005 Jun; 2(2):90-7. PubMed ID: 16091254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiviral treatment regimens].
    Esser S
    Hautarzt; 2006 Nov; 57(11):961-2, 964-8. PubMed ID: 17053925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.
    Hamer DH
    Curr HIV Res; 2004 Apr; 2(2):99-111. PubMed ID: 15078175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to limit immune-activation in HIV patients.
    Bandera A; Colella E; Rizzardini G; Gori A; Clerici M
    Expert Rev Anti Infect Ther; 2017 Jan; 15(1):43-54. PubMed ID: 27762148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antiretroviral therapy on immunity in patients infected with HIV.
    Feola DJ; Thornton AC; Garvy BA
    Curr Pharm Des; 2006; 12(9):1015-22. PubMed ID: 16515483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients.
    Deeks SG
    Lancet; 2006 Mar; 367(9512):711-3. PubMed ID: 16517257
    [No Abstract]   [Full Text] [Related]  

  • 8. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
    Forde J; Volpe JM; Ciupe SM
    Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials.
    Feng Q; Zhou A; Zou H; Ingle S; May MT; Cai W; Cheng CY; Yang Z; Tang J
    BMJ; 2019 Jul; 366():l4179. PubMed ID: 31285198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanochemistry-based immunotherapy for HIV-1.
    Lori F; Calarota SA; Lisziewicz J
    Curr Med Chem; 2007; 14(18):1911-9. PubMed ID: 17691933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.
    Trono D; Van Lint C; Rouzioux C; Verdin E; Barré-Sinoussi F; Chun TW; Chomont N
    Science; 2010 Jul; 329(5988):174-80. PubMed ID: 20616270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Towards eradication of human immunodeficiency virus (HIV)?].
    Katlama C
    Bull Acad Natl Med; 2013 Jun; 197(6):1177-85. PubMed ID: 25803930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of antiretroviral-drug-resistant HIV-1 infection.
    Deeks SG
    Lancet; 2003 Dec; 362(9400):2002-11. PubMed ID: 14683662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of finding a cure for HIV infection.
    Richman DD; Margolis DM; Delaney M; Greene WC; Hazuda D; Pomerantz RJ
    Science; 2009 Mar; 323(5919):1304-7. PubMed ID: 19265012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current problems and the future of antiretroviral drug trials.
    Lange JM
    Science; 1997 Apr; 276(5312):548-50. PubMed ID: 9148417
    [No Abstract]   [Full Text] [Related]  

  • 19. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral drugs in HIV-infected children.
    Viganò A; Manfredini V; Penagini F; Giacomet V; Zuccotti GV
    Pharmacol Res; 2011 Jul; 64(1):1-3. PubMed ID: 21255650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.